Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2S,3S)-3-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-oxo-1-pyrrolidin-1-ylbutan-2-amine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the class of alpha amino acid amides. It features a pyrrolidine amide structure with a substituted oxadiazole and methylsulfonylphenyl group. The molecule has been identified as an experimental agent and is not approved for clinical use or marketed under any brand name. There are no known clinical trials or approved indications for this compound. Based on available chemical biology data and structural similarity to other compounds in its class, it may act as an inhibitor of dipeptidyl peptidases such as DPP-IV (dipeptidyl peptidase 4), DPP8/9 (dipeptidyl peptidase 8/9), and possibly DPP-II; however, there is no direct evidence of its mechanism in humans or animals[2]. No developer or manufacturer information is available.
- Other names
- (2S,3S)-2-amino-3-[3-(4-methanesulfonylphenyl)-1,2,4-oxadiazol-5-yl]-1-(pyrrolidin-1-yl)butan-1-one(2S,3S)-2-Amino-3-{3-[4-(methylsulfonyl)phenyl]-1,2,4-Oxadiazol–5-Yl}-1-(Pyrrolidin–1-Yl)Butan–one
02
Targets
DPP8 (Dipeptidyl peptidase 8)DPP-4 (Dipeptidyl Peptidase-IV)DPP7 (Dipeptidyl peptidase 7)DPP9 (Dipeptidyl Peptidase 9)
Beyond the preview
Go deeper on (2S,3S)-3-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-oxo-1-pyrrolidin-1-ylbutan-2-amine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (2S,3S)-3-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-oxo-1-pyrrolidin-1-ylbutan-2-amine.